Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vasopressin V2 Receptor Antagonist · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Vasopressin V2 Receptor Antagonist | DRUG | - |
* Men or women with chronic heart failure (NYHA Class IIIB and IV). * Women must be post-menopausal or surgically sterilized; they cannot be pregnant or nursing. * Age 21 to 80 years. * Chronic heart failure of at least 3 months duration. For 2 months prior to screening, patients must have had sympt...
Vasopressin V2 Receptor Antagonist is an investigational small molecule being studied for the treatment of chronic heart failure. It is a vasopressin V2 receptor antagonist, which means it blocks the action of vasopressin on V2 receptors. The drug is currently in Phase 2 clinical development.
Sanofi (ticker: SNY) is developing Vasopressin V2 Receptor Antagonist. The drug is an investigational small molecule in Phase 2 clinical development for chronic heart failure, a cardiovascular condition.
Vasopressin V2 Receptor Antagonist is in Phase 2 clinical development. It is an investigational drug for chronic heart failure and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed.
Vasopressin V2 Receptor Antagonist has one completed Phase 2 clinical trial, NCT00032747, titled "Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT)." The trial enrolled 338 participants with chronic heart failure in the United States, Canada, and the United Kingdom.
Vasopressin V2 Receptor Antagonist targets the vasopressin V2 receptor. By blocking this receptor, the drug is designed to counteract the effects of vasopressin, which is relevant to its potential use in chronic heart failure. The drug is a small molecule in Phase 2 development.
Vasopressin V2 Receptor Antagonist is the drug being studied in the AQUAVIT clinical trial, but AQUAVIT is the name of the trial, not an alternative name for the drug. The trial is titled "Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT)."